Mesoblast Limited (ASX:MSB)

Market Cap	2.77B +38.6%
Revenue (ttm)	98.02M +1,053.2%
Net Income	-141.48M
EPS	-0.11
Shares Out	1.30B
PE Ratio	n/a
Forward PE	410.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,762,077
Average Volume	3,991,359
Open	2.160
Previous Close	2.140
Day's Range	2.130 - 2.180
52-Week Range	1.527 - 3.310
Beta	0.82
RSI	48.54
Earnings Date	May 25, 2026

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Financial numbers in USD